RESISTANCE ‑ POLYMYXIN E IN ACINETOBACTER BAUMANNII ISOLATED FROM PATIENTS IN THE WOUND UNIT
Journal: Matrix Science Pharma (MSP)
Letter to Editor
This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited
DOI: 10.4103/mtsp.mtsp_22_24_1
ABSTRACT
Polymyxin E is the last antibiotic effective against multidrug‑resistant (MDR) Acinetobacter baumannii infections. It disorders bacterial cell membranes, leading to cell death, but it has significant nephrotoxicity. Due to the rise of resistant strains for colistin, its clinical use requires careful monitoring and consideration of combination therapies. This study aimed to identify resistance genes (mcr), assess prevalence, and analyze factors driving resistance to guide better antibiotic use and control its spread in healthcare settings. Three hundred specimens were collected for culturing from patients who were admitted to the Al‑Hilla Teaching Hospital for the period between May 2023 and March 2023 among which only 20 specimens possessed A. baumannii isolates carrying the mobilized colistin resistance gene (MCR) genes.
| Pages | 115-116 |
| Year | 2025 |
| Issue | 3 |
| Volume | 9 |
